Helena Strigård

May 15, 2024

Discover more

Placeholder image for Amarna Therapeutics and NorthX Biologics finalize agreement to advance Nimvec™ AM510 gene therapy toward clinical trials for type 1 diabetes

July 8, 2025

Amarna Therapeutics and NorthX Biologics finalize agreement to advance Nimvec™ AM510 gene therapy toward clinical trials for type 1 diabetes

Amarna Therapeutics, a privately held biotechnology company pioneering transformative gene therapies, today announced the formalization of an agreement with NorthX Biologics, a leading biologics manufacturing partner, to accelerate the development ...

May 14, 2025

NorthX Biologics secures significant growth investment from Signet Healthcare Partners

NorthX Biologics, a leading Nordic biopharmaceutical Contract, Development, and Manufacturing Organization (CDMO), is pleased to announce a significant growth investment from Signet Healthcare Partners (Signet), a U.S.-based healthcare private equity ...

May 7, 2025

NorthX Biologics appoints Johanna Magnusson as Chief Operating Officer

Biopharmaceutical contract development and manufacturing organization (CDMO) NorthX Biologics is pleased to announce the appointment of Johanna Magnusson as Chief Operating Officer. With over two decades of leadership experience in ...